Profitelligence Profitelligence · Filing Ledger Open A research →

Form 8-K · Current Report · Filed 2025-07-15

Agilent Announces CFO Transition

On July 11, 2025, Agilent Technologies, Inc.

Filer
Agilent Technologies Inc. A · NYSE
Filed
Accession
0001193125-25-159100
CIK
0001090872
Signal
High impactHealthcare

Details

announced the resignation of its Chief Financial Officer, Robert W. McMahon, effective July 31, 2025. Rodney Gonsalves, Agilent's current corporate controller, has been appointed as interim CFO. The company also disclosed this transition under Regulation FD on July 15, 2025.

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

CFO Resignation New CFO Appointed
Item 7.01

Regulation FD Disclosure

Regulation FD Disclosure
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$120.08

Next session

-5.5%

Since filing

+15.2%

Latest close

$138.37

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from A reporting the same item, with the next session's move:

Exhibits (1)

About Agilent Technologies Inc.

Agilent Technologies Inc. is a global leader in the development and provision of life sciences, diagnostics, and applied chemical markets. Primarily focused on delivering superior analytical instruments, software, services, consumables, and reagents, the company plays a critical role in supporting the research needs of pharmaceutical, biotechnology, and government laboratories. Agilent's robust portfolio includes innovative solutions for genomics, proteomics, and metabolomics, aiding in critical areas such as disease research, food safety, and environmental analysis. Established in 1999 as a spin-off from Hewlett-Packard, the company leverages its heritage of technological innovation to enhance analytical capabilities for its clients. Agilent's significant contributions to health and safety applications underscore its importance in advancing scientific understanding and supporting public health initiatives worldwide.

Exchange NYSE Industry Diagnostics & Research Company website ↗

Never miss another A filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts